Skip to main content
. 2021 Aug 2;11(8):138. doi: 10.1038/s41408-021-00530-3

Fig. 4. Kinetics of NAbs in symptomatic MM patients on treatment with Belantamab mafodotin or anti-CD38-based combinations compared with MM patients off treatment and MM patients on treatment with other therapeutic regimens.

Fig. 4

Patients on Belantamab mafodotin or anti-CD38 combinations had significantly lower NAbs on day 50.